ES3058587T3 - Pyrazole derivatives as h4 antagonist compounds - Google Patents
Pyrazole derivatives as h4 antagonist compoundsInfo
- Publication number
- ES3058587T3 ES3058587T3 ES19794235T ES19794235T ES3058587T3 ES 3058587 T3 ES3058587 T3 ES 3058587T3 ES 19794235 T ES19794235 T ES 19794235T ES 19794235 T ES19794235 T ES 19794235T ES 3058587 T3 ES3058587 T3 ES 3058587T3
- Authority
- ES
- Spain
- Prior art keywords
- mmol
- methyl
- compound
- pyrazol
- intermediate compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1817047.2A GB201817047D0 (en) | 2018-10-19 | 2018-10-19 | H4 antagonist compounds |
| PCT/GB2019/052997 WO2020079457A1 (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as h4 antagonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3058587T3 true ES3058587T3 (en) | 2026-03-11 |
Family
ID=64453795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19794235T Active ES3058587T3 (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as h4 antagonist compounds |
Country Status (13)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005858D0 (en) * | 2020-04-22 | 2020-06-03 | Heptares Therapeutics Ltd | H4 Antagonist compounds |
| GB202019667D0 (en) * | 2020-12-14 | 2021-01-27 | Heptares Therapeutics Ltd | H4 antagonist comnpounds |
| KR102655210B1 (ko) * | 2021-03-26 | 2024-04-08 | 주식회사 스탠다임 | 아데노신 a2a 수용체 길항제 및 이의 용도 |
| WO2022232259A1 (en) * | 2021-04-28 | 2022-11-03 | Cornell University | Soluble adenylyl cyclase (sac) inhibitors and uses thereof |
| EP4421067A4 (en) * | 2021-10-19 | 2026-01-14 | Unimatec Co Ltd | PYRAZOLE COMPOUND CONTAINING FLUORIDE AND ITS PRODUCTION PROCESS |
| KR102621694B1 (ko) * | 2022-09-15 | 2024-01-08 | 주식회사 스탠다임 | 아데노신 a2a 수용체 길항제 및 이의 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000169475A (ja) | 1998-07-24 | 2000-06-20 | Dai Ichi Seiyaku Co Ltd | ピラゾ―ル誘導体およびその塩 |
| US6573377B1 (en) * | 1998-07-24 | 2003-06-03 | Daiichi Pharmaceuticals Co., Ltd. | Pyrazole derivatives and salts thereof |
| WO2005054239A1 (en) | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
| NL2000323C2 (nl) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| EP2066645A2 (en) | 2006-09-12 | 2009-06-10 | UCB Pharma S.A. | 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions |
| US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
| CL2008000467A1 (es) | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| WO2009068512A1 (en) | 2007-11-30 | 2009-06-04 | Palau Pharma, S. A. | 2 -amino-pyrimidine derivatives as histamine h4 antagonists |
| PE20091524A1 (es) | 2007-12-19 | 2009-09-25 | Palau Pharma Sa | Derivados de 2-aminopirimidina |
| RU2489430C2 (ru) | 2007-12-21 | 2013-08-10 | Палау Фарма, С.А. | Производные 4-аминопиримидина |
| AR074199A1 (es) | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer. |
| TW201035078A (en) | 2009-03-20 | 2010-10-01 | Incyte Corp | Substituted heterocyclic compounds |
| WO2011059839A1 (en) | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
| JP5781537B2 (ja) | 2009-12-23 | 2015-09-24 | メディシス ファーマシューティカル コーポレイション | ヒスタミンｈ４受容体アンタゴニストとしてのアミノアルキルピリミジン誘導体 |
| AR093512A1 (es) | 2012-11-16 | 2015-06-10 | Merck Patent Gmbh | Derivados heterociclicos como moduladores de la actividad de cinasas |
| JP2019525929A (ja) | 2016-07-28 | 2019-09-12 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｐａｒｋｉｎ酵素機能の小分子活性化因子 |
-
2018
- 2018-10-19 GB GBGB1817047.2A patent/GB201817047D0/en not_active Ceased
-
2019
- 2019-10-21 WO PCT/GB2019/052997 patent/WO2020079457A1/en not_active Ceased
- 2019-10-21 MX MX2021004280A patent/MX2021004280A/es unknown
- 2019-10-21 ES ES19794235T patent/ES3058587T3/es active Active
- 2019-10-21 EP EP19794235.2A patent/EP3867248B1/en active Active
- 2019-10-21 JP JP2021521390A patent/JP7532353B2/ja active Active
- 2019-10-21 CA CA3116628A patent/CA3116628A1/en active Pending
- 2019-10-21 US US17/285,776 patent/US12234227B2/en active Active
- 2019-10-21 BR BR112021007372-8A patent/BR112021007372A2/pt unknown
- 2019-10-21 AU AU2019360428A patent/AU2019360428B2/en active Active
- 2019-10-21 KR KR1020217014805A patent/KR102873380B1/ko active Active
- 2019-10-21 CN CN201980084053.7A patent/CN113272297B/zh active Active
- 2019-10-21 SG SG11202103133QA patent/SG11202103133QA/en unknown
-
2024
- 2024-09-05 US US18/826,098 patent/US20250115587A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022507013A (ja) | 2022-01-18 |
| EP3867248A1 (en) | 2021-08-25 |
| US20210300906A1 (en) | 2021-09-30 |
| WO2020079457A1 (en) | 2020-04-23 |
| KR20210079318A (ko) | 2021-06-29 |
| CA3116628A1 (en) | 2020-04-23 |
| BR112021007372A2 (pt) | 2021-07-20 |
| KR102873380B1 (ko) | 2025-10-23 |
| GB201817047D0 (en) | 2018-12-05 |
| SG11202103133QA (en) | 2021-05-28 |
| US12234227B2 (en) | 2025-02-25 |
| CN113272297B (zh) | 2024-03-19 |
| AU2019360428A1 (en) | 2021-04-29 |
| MX2021004280A (es) | 2021-05-31 |
| AU2019360428B2 (en) | 2024-05-09 |
| CN113272297A (zh) | 2021-08-17 |
| EP3867248C0 (en) | 2025-12-10 |
| US20250115587A1 (en) | 2025-04-10 |
| JP7532353B2 (ja) | 2024-08-13 |
| EP3867248B1 (en) | 2025-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2987196T3 (es) | Derivados de pirazolilo útiles como agentes antineoplásicos | |
| ES2682493T3 (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de FGFR4 | |
| US9573969B2 (en) | Compounds and compositions as kinase inhibitors | |
| US20250115587A1 (en) | Pyrazole derivatives as h4 antagonist compounds | |
| CN112469720B (zh) | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 | |
| JP6404332B2 (ja) | 新規な、ＮＩＫ阻害剤としての３−（１Ｈ−ピラゾール−４−イル）−１Ｈ−ピロロ［２，３−ｃ］ピリジン誘導体 | |
| EP2943485B1 (en) | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors | |
| ES2685839T3 (es) | Inhibidores de RORC2 heterobicicloarilo y procedimientos de uso de los mismos | |
| AU2017208555B2 (en) | New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | |
| BR112016011024B1 (pt) | Composto, composição farmacêutica, e, usos dos mesmos | |
| CN107849013A (zh) | 作为dub抑制剂用于治疗癌症的氰基吡咯烷类 | |
| CA2921959A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
| PH12015502047B1 (en) | Novel pyrimidine and pyridine compounds and their usage | |
| US20250129070A1 (en) | Bifunctional androgen receptor compounds | |
| WO2025099307A1 (en) | Compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| EP3986405A1 (en) | Compounds for inhibiting fgfr4 | |
| EP4507789A1 (en) | Pyrido[3,2-d]pyrimidines as hpk1 inhibitors | |
| CN119894908A (zh) | Egfr抑制剂和其用途 | |
| RU2821516C2 (ru) | Пиразольные производные в качестве соединений-антагонистов h4 | |
| CN115916770B (zh) | H4拮抗剂化合物 | |
| TWI673268B (zh) | 作為ｆｇｆｒ４抑制劑之稠環雙環吡啶基衍生物 | |
| BR112022012128B1 (pt) | Derivados de pirazolila úteis como agentes anticancerígenos, seus usos, composição e combinação farmacêuticas, e kit | |
| HK1224664B (en) | New 3-(1h-pyrazol-4-yl)-1h-pyrrolo(2,3-c) pyridine derivatives as nik inhibitors |